Table 1.
Patient Characteristics
| Study Case # | Age at DLI /Sex | Donor | HCT Graft | HCT to Chemotherapy (Months) | Chemotherapy to DLI (Days) | Chemotherapy | Remission at DLI |
|---|---|---|---|---|---|---|---|
| Acute myeloid leukemia | |||||||
| 2 | 24 M | Sib | PBSC | 8.4 | 68 | HCVAD, HDAC/MTX | N (Extramedullary) |
| 3 | 56 M | URD | BM | 6.4 | 61 | Mylotarg | N (Extramedullary) |
| 5 | 61 F | Sib | BM | 121.3 | 40 | IDR + AraC | Y |
| 17 | 40 F | Sib | PBSC | 16.8 | 53 | IDR + AraC | N (BM FCM <5%) |
| 7 | 38 M | Sib | BM | 63.8 | 50 | Mylotarg | N (Cytogenetic) |
| 8 | 20 M | Sib | PBSC | 5.8 | 75 | HDAC + MIT | N (Extramedullary) |
| 10 | 60 F | Sib | PBSC | 25.9 | 68 | IDR + AraC | Y |
| 11 | 33 M | Sib | PBSC | 6.0 | 50 | IDR + AraC + ETP | Y |
| 12 | 22 M | Sib | PBSC | 7.5 | 54 | MIT + ETP | Y |
| 14 | 35 F | Sib | PBSC | 17.9 | 77 | MIT + ETP | Y |
| 15 | 21 F | Sib | PBSC | 3.2 | 36 | FLAG + IDR | N (BM FCM 5%) |
| Acute lymphoblastic leukemia | |||||||
| 1* | 24 F | Sib | BM | 13.4 | 63 | HDAC + ETP | N (BM FCM 0.1%) |
| 4 | 34 M | URD | PBSC | 8.7 | 62 | HCVAD | Y |
| 16 | 19 F | Sib | PBSC | 18.5 | 83 | VCR + DNR + DEX + PEG-ASP | Y |
| 9* | 21 F | URD | PBSC | 11.9 | 91 | VCR + DNR + PSL, FLAG | N (BM FCM 0.1%) |
| 13 | 29 M | URD | PBSC | 8.4 | 52 | VCR + AraC + MTX | Y |
| 6 | 50 F | Sib | PBSC | 11.8 | 50 | VCR + DNR + PSL + L-ASP | N (Cytogenetic) |
HCT indicates hematopoietic cell transplantation; Sib, sibling donor; URD, unrelated donor; PBSC, peripheral blood stem cell; BM, bone marrow; HCVAD, fractionated cyclophosphamide + vincristine + dexamethasone + doxorubicin; HDAC, high-dose cytarabine; IDR, idarubicin; AraC, cytarabine; FCM, flow cytometry; MIT, mitoxantrone; ETP, etoposide; FLAG, fludarabine + cytarabine + granulocyte colony-stimulating factor; DNR, daunorubicin; PSL, prednisone; VCR, vincristine; L-ASP, L-asparaginase; DEX, dexamethasone; PEG-ASP, polyethylene glycosylated asparaginase.
*
Philadelphia chromosome-positive acute lymphoblastic leukemia